Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report by Keishiro Aoyagi et al.
CASE REPORT Open Access
Long-term survival of a patient with small
cell carcinoma of the stomach with
metachronous lung metastases treated by
multimodal therapy: a case report
Keishiro Aoyagi*, Junya Kizaki, Taro Isobe and Yoshito Akagi
Abstract
A 69-year-old man was referred to our institution for treatment of gastric cancer. Type 2 gastric cancer was found
on the anterior wall of the lower body of the stomach.
The patient underwent distal gastrectomy, D2 lymph node dissection, and Roux-en-Y reconstruction with curative
resection. The tumor was diagnosed as a small cell carcinoma of the stomach. Recurrence occurred in the lung
after surgery. The patient underwent several chemoradiation therapy regimens, including cisplatin + irinotecan +
radiation, S-1 + paclitaxel, amrubicin, carboplatin + etoposide, nogitecan, and docetaxel for lung metastases and
radiation for brain and bone metastases for 43 months. He finally died of brain metastases 74 months after surgery
(47 months after recognition of the lung metastases). Long continuous multimodal treatment including surgery,
regimens for small cell lung cancer, S-1, taxanes, and radiation was thought to prolong the survival of this man
with small cell carcinoma of the stomach.
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Background
The World Health Organization classification of 2010
defined neuroendocrine carcinoma (NEC) as a subgroup
of neuroendocrine neoplasms. Neuroendocrine neo-
plasms are classified as neuroendocrine tumors or NECs
according to their bioactivity, which is determined by
the mitotic rate and Ki67 index [1]. The Japanese classi-
fication of gastric carcinoma defines NEC as a special
type in the histological classification of gastric tumors
and considers NEC to be either small cell type or large
cell type [2]. NEC of the stomach is relatively rare,
accounting for 0.1 to 0.6 % of all gastric carcinomas
[3, 4]. A high frequency of capillary invasion and
hematogenous metastases, such as to the liver and
lung, is seen with NEC, and the prognosis is poor.
Moreover, a standard chemotherapy regimen for NEC
of the stomach has not yet been established.
We present a case involving a patient with small cell
carcinoma of the stomach with metachronous lung me-
tastases who survived for 74 months after surgery with
multimodal therapy including surgery, chemotherapy,
and radiation.
Case presentation
A 69-year-old man with a history of diabetes mellitus
and hypertension visited a local hospital with the com-
plaint of a heavy feeling in the stomach and epigastric
distress. An X-ray examination and upper gastrointes-
tinal endoscopic examination revealed a type 2 tumor on
the anterior wall of the lower body of the stomach. The
pathological diagnosis based on a biopsy specimen from
the tumor lesion was anaplastic carcinoma. The patient
was referred to the Center of Gastroenterology, Kurume
University Hospital, for further examination and treat-
ment for gastric cancer on 7 December 2005. The liver,
spleen, and tumor were not palpable on physical exam-
ination. The serum levels of carcinoembryonic antigen,
carbohydrate antigen 19-9, and cancer antigen 72-4 were
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within the reference range. An X-ray examination
showed an irregular round ulcerative lesion surrounding a
well-demarcated, smooth protrusion on the anterior wall
of the lower body of the stomach. An upper gastrointes-
tinal endoscopic examination showed an irregular central
ulceration with clearly demarcated and raised margins,
type 2, on the anterior wall of the lower body of the stom-
ach (Fig. 1). The pathological diagnosis based on a biopsy
specimen was a poorly differentiated adenocarcinoma.
Abdominal computed tomography (CT) showed no meta-
static lesions in the liver and no lymph node metastases.
The patient was admitted to the hospital and underwent
distal gastrectomy with D2 lymph node dissection and
Roux-en-Y reconstruction on 25 January 2006.
The primary tumor was palpable on the anterior
wall of the lower body, and no exposed tumor was
seen on the serosa. No macroscopic metastases were
found in the lymph nodes, liver, or peritoneum. On
macroscopic examination, the specimen resected from
the anterior wall of the lower body was sharply de-
marcated, type 2, and 43 × 41 mm in size (Fig. 2). A
lower-power view of a cross section of the specimen
showed medullary infiltration of neoplastic cells,
mainly in the submucosa. A low-power histological
view showed that the tumor had invaded the muscu-
laris propria in some parts (Fig. 3a). The high-power
view showed monotonous tumor cells with little cyto-
plasm and round chromatin-rich nuclei; many mitotic
figures were also seen (183 per 10 high-power fields)
(Fig. 3b). A well-differentiated tubular adenocarcin-
oma was recognized in one part of the surrounding
elevation (Fig. 3c). The tumor showed positive immu-
nohistochemical staining with chromogranin A and
synaptophysin (Fig. 3d, e). The Ki67 index was 66.7 %
(Fig. 3f ). Thus, the histological diagnosis was small
cell carcinoma of the stomach with moderate lymph-
atic and venous invasion. No metastases were seen in
the lymph nodes on histological examination. The
final diagnosis was a gastric cancer type 2 (LM),
T2N0H0P0M0 stage IB. The surgery was evaluated as
a curative resection with a negative resection margin (R0).
The patient’s postoperative course was good, and he was
discharged from the hospital on 10 February 2006.
The patient was then administered 600 mg of doxiflur-
idine as postoperative adjuvant chemotherapy for
27 months. However, a lung tumor was seen in the left
lower lung field on the chest X-ray on 28 April 2008.
Chest CT showed a well-demarcated mass, 20 mm in
size, at S10 of the left lung (Fig. 4). Small cell carcinoma
cells were confirmed by transbronchial lung biopsy.
Thus, this tumor was diagnosed as lung recurrence of
gastric small cell carcinoma. The patient began treat-
ment with chemotherapy comprising cisplatin (CDDP)
(90 mg, day 1) + irinotecan (CPT-11) (90 mg; days 1, 8,
and 15) (28-day cycle); radiation of 45 Gy (150 cGy ×
2 × 15 days) was added. After six courses of this regimen,
chest CT revealed no mass at S10 of the left lung on 21
January 2009 (Fig. 5). The patient was then followed
carefully without chemotherapy. Chest CT subsequently
revealed regrowth of the mass at S10 of the left lung on
15 April 2009. The patient was administered S-1 (80 mg,
days 1–14) + paclitaxel (PTX) (70 mg, days 1 and 8)
(21-day cycle) as second-line chemotherapy from 12
May 2009 to 10 March 2010. Although nine courses of
this regimen were administered, the size of the mass at
S10 of the left lung increased. Amrubicin (60 mg, days
1–3) (21-day cycle) was then administered as third-line
chemotherapy in six courses from 6 April to 11 August
2010. However, chest CT on 31 August 2010 showed
Fig. 1 Upper gastrointestinal endoscopic examination. An irregular
central ulceration with clearly demarcated and raised margins, type
2, is present on the anterior wall of the lower body of the stomach
Fig. 2 Macroscopic examination. The specimen resected from the
anterior wall of the lower body was sharply demarcated, type 2, and
43 × 41 mm in size




Fig. 3 Hematoxylin-eosin staining and immunohistochemistry. a The tumor is invading the muscularis propria in some parts (HE staining, ×40).
b Monotonous tumor cells have little cytoplasm and round chromatin-rich nuclei; many mitotic figures are also seen (183 per 10 high-power
fields) (HE staining, ×400). c In one part of the surrounding elevation, a well-differentiated tubular adenocarcinoma is seen (HE staining, ×40). The
tumor shows positive staining with d chromogranin A (×400) and e synaptophysin (×400). f Many Ki67-positive cells are seen, and the Ki67 index
is 66.7 % (×400)
Fig. 4 Chest computed tomography on 21 May 2008. Chest computed tomography shows a well-demarcated 20-mm mass at S10 of the left lung (arrow)
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that the mass lesion at S10 had increased to 9 × 26 mm
and a lymph node at the hilum of the left lung had swol-
len to 20 mm (Fig. 6). Carboplatin (CBDCA) (280 mg,
day 1) + etoposide (130 mg, days 1–3) (21-day cycle)
was then administered in four courses as fourth-line
chemotherapy from 28 September to 4 December 2010.
The serum level of cytokeratin 19 fragment (CYFRA)
was slightly elevated (Fig. 7) but that of neuron-specific
γ-enolase (NSE) was within the reference range during
fourth-line chemotherapy. Grade 3 and 4 adverse events
were leukopenia and neutropenia, respectively. However,
these adverse events were recovered during administra-
tion of a granulocyte colony-stimulating factor. Chest
CT on 7 December 2010 showed that the mass lesion at
S10 had increased to 46 × 30 mm and that the swollen
lymph node at the hilum of the left lung had increased
to 25 mm. Nogitecan (1.1 mg, days 1–5) (28-day cycle)
was thus administered as fifth-line chemotherapy in six
courses from 5 January to 21 May 2011. Chest CT then
revealed that the mass lesion at S10 increased from 48 ×
32 mm on 1 March to 65 × 40 mm on 7 June 2011 and a
small amount of effusion had developed; however, the
lymph node at the hilum of the left lung had not
changed in size. Docetaxel (70 mg, day 1) (21-day
cycle) was then given as sixth-line chemotherapy in
eight courses from 14 June 2011 to 16 January 2012.
Chest CT on 6 September 2011 revealed that the
mass at S10 had not changed; however, the swollen
lymph node at the hilum of the left lung had de-
creased from 30 × 26 mm to 26 × 18 mm.
Severe (grade 3 or 4) adverse effects did not occur ex-
cept those associated with CBDCA + etoposide.
The patient developed bradypragia and higher brain
dysfunction in mid-October 2011. Brain magnetic res-
onance imaging (MRI) revealed multiple brain metas-
tases. Moreover, the patient developed lower back
pain in mid-January, and the serum level of CYFRA
increased to >30 ng/mL (Fig. 7). MRI of the thoracic
and lumbar vertebrae on 31 January 2012 showed
bone metastases in the thoracic vertebrae.
The patient was transferred to another hospital for
palliative care. He died of brain metastases 74 months
after surgery (47 months after recognition of the lung
metastases).
Fig. 5 Chest computed tomography on 21 January 2009. The mass at S10 of the left lung is not detected
Fig. 6 Chest computed tomography on 31 August 2010. Swelling of a lymph node, 20 mm in size, is recognized at the hilum of the left lung (arrow)
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Discussion
For patients with gastric NEC, the National Comprehen-
sive Cancer Network guideline recommends multimodal
therapy including surgical resection of the stomach and
postoperative administration of a regimen for small cell
lung cancer, such as CDDP + etoposide (ETP), CDDP +
CPT-11, or CBDCA + ETP [5]. In our case, the patient
had been administered doxifluridine as postoperative ad-
juvant chemotherapy for 27 months; nevertheless, recur-
rence from gastric small cell carcinoma was recognized.
Therefore, we concluded that doxifluridine had no clin-
ical effect on this cancer and started new treatment
comprising CDDP + CPT-11 + radiation. Various regi-
mens for small cell lung cancer were administered in the
present case, including CDDP + CPT-11 + radiation
(first-line), amrubicin (third-line), CBDCA + ETP
(fourth-line), and nogitecan (fifth-line) (Fig. 7). After
first-line therapy, a complete response of the metastatic
site in the lung was confirmed on chest CT. S-1 alone or
S-1 + CDDP has been administered as the standard
treatment for advanced gastric cancer based on the Japa-
nese gastric cancer treatment guideline [6] and two
phase-III trials (SPIRITS trial: S-1 vs. S-1 + CDDP [7]
and JCOG 9912 trial: fluorouracil vs. CPT-11 + CDDP
vs. S-1 [8]). Additionally, several case reports docu-
mented good clinical effects of S-1 or S-1 + CDDP for
NEC of the stomach in Japan [9–11]. Hainsworth et al.
[12] performed a phase-II trial of three anticancer drugs
including taxane (PTX, CBDCA, and ETP) in patients
with poorly differentiated NEC of the gastrointestinal
tract and reported a response rate of 53 % and median
progression-free survival of 14.5 months. In the present
case, no severe adverse effects occurred with the admin-
istration of S-1 + PTX as second-line therapy (nine
courses for 10 months) and docetaxel alone as sixth-line
therapy (eight courses for 7 months) (Fig. 7). Some case
reports have described good clinical responses with mul-
tiple combined chemotherapy for NEC of the stomach,
such as CDDP + cyclophosphamide + epirubicin + vin-
cristine sulfate, and ETP + CDDP + doxorubicin hydro-
chloride [13, 14]. However, the adverse effects of these
regimens were severe. All six regimens administered in
the present case involved one or two drugs, and it was
possible to continue the chemoradiation therapy for
43 months (Fig. 7).
While the patient underwent the first regimen, the
metastatic single nodule was localized to S10 of the left
lung; thus, the radiation was thought to be effective as
local therapy for this metastatic nodule. Moreover, radi-
ation was performed for brain and bone metastasis and
was thought to be useful for prolonged survival and im-
provement in the patient’s quality of life.
Fig. 7 Summary of postoperative course. After recurrence in the lung at 27 months after surgery, the patient was administered first-line
chemotherapy with radiation for 5 months. The clinical effect was CR. However, regrowth was recognized at 39 months. We administered
second-line chemotherapy for 10 months and third-line chemotherapy for 4 months. The tumor slightly increased. Therefore, we administered fourth-line
chemotherapy for 2 months. However, the patient had severe adverse effects. Moreover, the tumor increased and a swollen lymph node was recognized
at 58 months. We changed to fifth-line chemotherapy. However, the tumor increased and effusion developed at 64 months. We administered sixth-line
chemotherapy for 7 months. The tumor in the lung had not changed, but brain (69 months) and bone metastases (72 months) were recognized. The
serum level of CYFRA was initially slightly elevated; it became upregulated with the development of progressive disease, finally reaching >30 ng/mL with
brain and bone metastases. The CEA and CA19-9 levels were within the reference range
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This case suggests that the addition of S-1 and taxane
to a small cell lung cancer regimen with radiation pro-
longs the prognosis of recurrent NEC of the stomach.
NSE is reportedly a sensitive tumor marker for neuro-
endocrine tumors [15], but the NSE level was within the
reference range in the present case. Although CYFRA is
a sensitive marker for non-small-cell lung cancer [16], it
was a very sensitive marker for progression and metasta-
ses in the present case (Fig. 7).
Conclusions
The long-term continuous administration of regimens
for small cell lung cancer, including S-1 and taxanes
with one or two drugs and radiation, was thought to be
effective against recurrence of small cell carcinoma of
the stomach in the present case.
Consent
Written informed consent was obtained from the pa-
tient’s wife for publication of this case report and any
accompanying images. A copy of the written consent
is available for review by the Editor-in-Chief of this
Journal.
Abbreviations
CBDCA: carboplatin; CDDP: cisplatin; CPT-11: irinotecan; CT: computed
tomography; CYFRA: cytokeratin 19 fragment; ETP: etoposide; MRI: magnetic
resonance imaging; NEC: neuroendocrine carcinoma; NSE: neuron-specific
γ-enolase; PTX: paclitaxel.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KA participated in the conception, design, and analysis of this case report
and drafted the manuscript. JK and TI participated in the design and
coordination of the report and helped to draft the manuscript. YA was the
chief supervisor. All authors read and approved the final manuscript.
Authors’ information
KA is an assistant professor in the Department of Surgery, Kurume University
School of Medicine. JK and TI are research associates in the Department of
Surgery, Kurume University School of Medicine. YA is a professor in the
Department of Surgery, Kurume University School of Medicine.
Acknowledgements
The authors would like to express their sincere appreciation to Professor
Masayoshi Kage of the Department of Diagnostic Pathology, Kurume
University Hospital, for providing assistance with interpretation of the
pathological findings and performing the immunohistochemical work-up.
Received: 9 July 2015 Accepted: 20 December 2015
References
1. Rind G, Arnold R, Bosman FT, Capella C, Klimstra DS, Klöppel G, et al.
Nomenclature and classification of neuroendocrine neoplasms of the
digestive system: WHO classification of tumors of digestive system. 4th ed.
Lyon: WHO;2010. p. 13–4.
2. Japanese Gastric Cancer Association. Japanese classification of gastric
carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
3. Matsusaka T, Watanabe H, Enjoji M. Oat-cell carcinoma of the stomach.
Fukuoka Acta Med. 1976;67:65–73.
4. Watanabe H, Jass JR, Sobin LH. Histological typing of oesophageal and
gastric tumors. 2nd ed. Berlin: Springer; 1990. p. 19–28.
5. NCCN clinical practice guidelines in oncology neuroendocrine tumors v.1.
2011. http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.
pdf. Accessed 14 May 2015.
6. Association JGC. Japanese gastric cancer treatment guidelines. 2010 (ver. 3).
Gastric Cancer. 2011;14:113–23.
7. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al.
Randomized phase III study of S-1 alone versus S-1 cisplatin in the
treatment for advanced gastric cancer (the SPIRITS trial): a phase III trial.
Lancet Oncol. 2008;9:215–21.
8. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil
versus combination of irinotecan plus cisplatin versus S-1 in metastatic
gastric cancer: a randomized phase 3 study. Lancet Oncol. 2009;10:1063–9.
9. Hanada N, Inoue K, Osako T, Kuriwaki K, Shimajiri S, Mochinaga M. A case of
partial response in liver metastatic lesion from gastric endocrine cell
carcinoma treated with TS-1 (in Japanese with English abstract). Jpn J
Cancer Chemother. 2006;23:1143–6.
10. Kaneko S, Itsui Y, Hashiguchi M, Watanabe M, Yoshida R, Akashi T, et al. A
case of gastric neuroendocrine carcinoma with liver metastasis and portal
vein invasion successfully treated by S-1 and cisplatin chemotherapy (in
Japanese with English abstract). J Jpn Soc Gastroenterol. 2013;110:56–63.
11. Iwasaki K, Katayanagi S, Sumi T, Tsuchida A, Kawachi S, Shimazu M. A review
of 6 cases of endocrine carcinoma of the stomach (in Japanese with English
abstract). J Jpn Surg Assoc. 2014;75:2962–6.
12. Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel,
carboplatin, and etoposide in advanced poorly differentiated
neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
J Clin Oncol. 2006;24:3548–54.
13. Sakai K, Nomura H, Nogami T, Saeki T, Etoh Y, Imamura H, et al. A case of
complete remission of gastric endocrine cell carcinoma with multiple bone
metastasis by combination chemotherapy and high-dose chemotherapy
with autologous peripheral blood stem cell transplantation (in Japanese
with English abstract). Jpn J Cancer Chemother. 1997;24:2277–80.
14. Hirama K, Tsuchida H, Matsumoto K, Suzuki J, Nozaki T. Two cases of gastric
small cell carcinoma responding to postoperative chemotherapy with
modified EAP regimen (in Japanese with English abstract). J Jpn Surg Assoc.
1998;59:983–9.
15. Lindholm DP, Oberg K. Biomarkers and molecular imaging in
gastroenteropancreatic neuroendocrine tumors. Horm Metab Res. 2011;43:
832–7.
16. Xu Y, Xu L, Qiu M, Wang J, Zhou Q, Xu L, et al. Prognostic value of serum
cytokeratin 19 fragment (Cyfra21-1) in patients with non-small cell lung
cancer. Sci Rep. 2015;5:9444.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Aoyagi et al. Surgical Case Reports  (2015) 1:125 Page 6 of 6
